Agencies, Industry Look to Standardize, Focus Global Inspection Processes
This article was originally published in The Gold Sheet
Executive Summary
PIC/S, the world’s ‘club’ of pharmaceutical inspectorates, is considering making life easier for manufacturers by helping members align their views on deficiencies and reduce inspection redundancies. But much depends on the club’s ability to bring more inspectorates into the fold, particularly those of the emerging BRIC nations.
You may also be interested in...
PIC/S To Guide Member Inspectorates On Harmonizing GMP Deficiency Classifications
Draft guidance soon will help the world’s leading pharmaceutical inspectorates align views on which drug GMP deficiencies are considered major – and which are truly critical.
US FDA's Inspection Decisions To Be Swayed By Facility "History" With Foreign Regulators
Leveraging foreign surveillance inspections could help FDA ensure more sites are inspected more often.
BRIC Nations Slow to Join PIC/S Inspection Coordination Effort
PIC/S could play an even greater role in coordinating drug GMP inspections if its members included inspectorates of all the major drug exporting nations. While India appears to lack interest, Japan, China and others have been working to qualify for membership.